EdoxabaN or Warfarin Therapy In Device Procedures in Patients With Non-Valvular Atrial Fibrillation

Atrial Fibrillation Clinical Trial

— ENTICED-AF  

Official title:

Efficacy and Safety of Edoxaban or Warfarin Therapy In Cardiovascular Implantable Electrical Device Procedures in Patients With Non-valvular Atrial Fibrillation

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02561897
• Other study ID #: EPRF2015-01
• Status: Terminated
• Phase: Phase 4
• Start date: December 2015
• Est. completion date: December 2017

Study information

• Verified date: March 2017
• Source: Electrophysiology Research Foundation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective randomized comparative evaluation of Edoxaban and Warfarin for safety and efficacy in perioperative use in patients with non-valvular atrial fibrillation (AF) undergoing clinically indicated implantation or replacement of cardiovascular implantable electrical devices.The primary objective is to compare the rates of local and systemic bleeding in subjects randomized to Edoxaban compared to subjects randomized to continuous warfarin in within 30 days of cardiac rhythm device implant with concomitant non-valvular AF.

Description:

This is a prospective randomized comparative evaluation of Edoxaban and Warfarin for safety and efficacy in perioperative use in patients with non-valvular atrial fibrillation undergoing clinically indicated implantation or replacement of cardiovascular implantable electrical devices. This study is a randomized, open label, active-controlled trial with an open-label safety extension, designed to compare local and systemic bleeding within 30 days of cardiac rhythm device implant among subjects randomized to continuous Warfarin or interrupted (<24 hours) Edoxaban. The study will have three phases, a run in phase to establish stable warfarin therapy, an acute open label 30 day phase when subjects will be randomized in a 1:1 ratio to receive interrupted edoxaban or continuous warfarin followed by an open label follow up phase for an additional 5 months for safety monitoring. Drug transitions will be performed according to approved drug labeling.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: December 2017
• Est. primary completion date: September 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects with established atrial fibrillation (AF) and bradycardia on long term (>3 weeks) therapeutic oral anticoagulant (OAC) with warfarin or another OAC who are undergoing new pacemaker system implant or existing pacemaker system revision.

• Subjects with newly detected bradycardia -tachycardia syndrome and AF who have been recently (less than 3 weeks) started on warfarin, have a therapeutic international normalized ratio (INR) and no thrombus on trans-esophageal echocardiogram (TEE) who are undergoing a new pacemaker system implant or revision.

• Subjects with AF and ventricular tachyarrhythmias (VT or VF) or acquired structural heart disease who are candidates for implantable cardioverter-defibrillator (ICD) therapy and are on long term (>3 weeks) therapeutic OAC with warfarin or another OAC who are undergoing new ICD system implant or existing ICD system revision.

• Subjects with newly detected AF with VT or VF who have been recently (less than 3 weeks) started on warfarin, have a therapeutic INR and no thrombus on TEE who are undergoing ICD system implant or revision

Exclusion Criteria:

• Clinically significant valvular heart disease

• Subjects requiring cardiovascular implantable electrical device (CIED) lead extraction e.g. for device site infection, endocarditis, leads under advisory or other conditions warranting lead(s) system extraction.

• Recent (<1 month) myocardial infarction

• Documented left atrial (LA) thrombus on TEE

• Contraindications to anticoagulant therapy or adverse event with prior warfarin or edoxaban therapy

• Creatinine clearance <30ml/min or >95 ml/min

• Hepatic disease, advanced

• Recent stroke (<3 months) or thromboembolic event

• Recent (<3months) intracranial or other major bleeding event

• Use of concomitant dual antiplatelet therapy or other oral, subcutaneous or parenteral anticoagulant therapy

• Subjects on warfarin without therapeutic INR levels before study entry

• Subjects with other clinically significant medical condition

• Subjects with life expectancy < 1 year

• Lead extraction procedures

Related Conditions & MeSH terms

• Atrial Fibrillation

Intervention

Drug:
• Edoxaban

• Warfarin

Locations

Country	Name	City	State
United States	Electrophysiology Research Foundation	Warren	New Jersey

Sponsors (2)

Lead Sponsor	Collaborator
Electrophysiology Research Foundation	Axio Research Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Major Bleeding	Major local or systemic bleeding as defined in the protocol at 30 days after implant procedure	Within 30 days of procedure
Secondary	Thromboembolic and Cardiovascular Events	Thrombotic events (embolism or stroke) through 6 months following the procedure in the Edoxaban and Warfarin groups and the rates of MACE events through 6 months following the procedure in the Edoxaban and Warfarin groups	Within 6 months of procedure

External Links

•   Related Info